AU2022231007A1 - Methods for treating familial chylomicronemia syndrome - Google Patents

Methods for treating familial chylomicronemia syndrome Download PDF

Info

Publication number
AU2022231007A1
AU2022231007A1 AU2022231007A AU2022231007A AU2022231007A1 AU 2022231007 A1 AU2022231007 A1 AU 2022231007A1 AU 2022231007 A AU2022231007 A AU 2022231007A AU 2022231007 A AU2022231007 A AU 2022231007A AU 2022231007 A1 AU2022231007 A1 AU 2022231007A1
Authority
AU
Australia
Prior art keywords
patient
lomitapide
dosing period
dose
daily dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022231007A
Other languages
English (en)
Other versions
AU2022231007A9 (en
Inventor
Mark SUMERAY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amryt Pharmaceuticals Inc
Original Assignee
Amryt Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amryt Pharmaceuticals Inc filed Critical Amryt Pharmaceuticals Inc
Publication of AU2022231007A1 publication Critical patent/AU2022231007A1/en
Publication of AU2022231007A9 publication Critical patent/AU2022231007A9/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2022231007A 2021-03-03 2022-03-03 Methods for treating familial chylomicronemia syndrome Pending AU2022231007A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163155960P 2021-03-03 2021-03-03
US63/155,960 2021-03-03
US202163165457P 2021-03-24 2021-03-24
US63/165,457 2021-03-24
PCT/US2022/018672 WO2022187463A1 (en) 2021-03-03 2022-03-03 Methods for treating familial chylomicronemia syndrome

Publications (2)

Publication Number Publication Date
AU2022231007A1 true AU2022231007A1 (en) 2023-08-17
AU2022231007A9 AU2022231007A9 (en) 2024-09-19

Family

ID=80819670

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022231007A Pending AU2022231007A1 (en) 2021-03-03 2022-03-03 Methods for treating familial chylomicronemia syndrome

Country Status (10)

Country Link
US (1) US20240165093A1 (https=)
EP (1) EP4301361A1 (https=)
JP (1) JP2024508334A (https=)
KR (1) KR20230153375A (https=)
AU (1) AU2022231007A1 (https=)
BR (1) BR112023016943A2 (https=)
CA (1) CA3208189A1 (https=)
IL (1) IL305191A (https=)
MX (1) MX2023010297A (https=)
WO (1) WO2022187463A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3186856A1 (en) 2020-07-29 2022-02-03 Ruth NALLEN Lomitapide for use in methods of treating hyperlipidemia and hypercholesterolemia in pediatric patients

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595872A (en) 1992-03-06 1997-01-21 Bristol-Myers Squibb Company Nucleic acids encoding microsomal trigyceride transfer protein
US5883109A (en) 1996-07-24 1999-03-16 Bristol-Myers Squibb Company Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug
US6066653A (en) 1997-01-17 2000-05-23 Bristol-Myers Squibb Co. Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs
KR101494067B1 (ko) 2004-03-05 2015-02-16 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 부작용을 최소화하면서 과지질혈증 및 과콜레스테롤혈증과 연관된 질환 또는 질병의 치료 방법
BR102015025502B1 (pt) 2015-04-30 2022-06-21 Aegerion Pharmaceuticals, Inc Composição de lomitapida, tablete, produto de lomitapida, métodos para analisar uma composição de amostra de lomitapida e para determinar uma quantidade de uma impureza em uma amostra da composição

Also Published As

Publication number Publication date
IL305191A (en) 2023-10-01
BR112023016943A2 (pt) 2023-10-31
US20240165093A1 (en) 2024-05-23
AU2022231007A9 (en) 2024-09-19
KR20230153375A (ko) 2023-11-06
MX2023010297A (es) 2023-09-12
CA3208189A1 (en) 2022-09-09
JP2024508334A (ja) 2024-02-26
EP4301361A1 (en) 2024-01-10
WO2022187463A1 (en) 2022-09-09

Similar Documents

Publication Publication Date Title
US20220152058A1 (en) Methods and compositions for treating various disorders
US11672783B2 (en) Pharmaceutical combination comprising a selective S1P1 receptor agonist
US20240189311A1 (en) Combination Therapy of Obicetrapib and Ezetimibe for Use in Statin Intolerant Patients Suffering from Hyperlipidemia or Mixed Dyslipidaemia
US20240165093A1 (en) Methods for treating familial chylomicronemia syndrome
CA2959488C (en) Pharmaceutical composition and therapeutic combination comprising a cholesteryl ester transfer protein inhibitor and hmg coa reductase inhibitors
CA2818277A1 (en) Use of dronedarone for the preparation of a drug for use in the management of the risk of liver injury
US20250161273A1 (en) Pharmaceutical composition comprising diphenyldiazole derivatives and methods of use
KR20150002799A (ko) 할로페네이트 또는 할로펜산 및 소염제를 이용한 통풍 환자에서의 고요산혈증 치료 방법
WO2017023166A1 (en) Pharmaceutical composition and therapeutic combination comprising a cholesteryl ester transfer protein inhibitor and a cholesterol absorption inhibitor
RU2857392C2 (ru) Способы лечения синдрома семейной хиломикронемии
HK40115748A (zh) 包含二苯基二唑衍生物的药物组合物及其使用方法
EA052714B1 (ru) Фармацевтическая композиция, содержащая производные дифенилдиазола, и способ применения
JP2026500731A (ja) 医薬組合せおよび医薬組成物、ならびにその使用方法
CN106074559A (zh) 一种预防动脉粥样硬化的药物组合物及应用

Legal Events

Date Code Title Description
SREP Specification republished